Abstract
p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Current Cancer Drug Targets
Title: p53: Fighting Cancer
Volume: 4 Issue: 5
Author(s): Galina Selivanova
Affiliation:
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Abstract: p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Export Options
About this article
Cite this article as:
Selivanova Galina, p53: Fighting Cancer, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332934
DOI https://dx.doi.org/10.2174/1568009043332934 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Editorial (Thematic Issue: Endocrine Related Cancer: From Stem Cells to New Drug Targets)
Current Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design An Illustrative Review of Solid Pancreatic Masses: Differential Diagnostic Features of CT and MRI Findings
Current Medical Imaging The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) Application of Bioactive Compounds and Drugs to Target Epigenetic Enzymes and Non-coding RNAs, Exploiting New Delivery Systems for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in the Development of Selective TRPV1 Antagonists for Pain
Current Topics in Medicinal Chemistry Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology